Low-Dose Oral Minoxidil for Treatment of Androgenetic Alopecia and Telogen Effluvium in a Pediatric Population: A Descriptive Study

    B. de Nicolas-Ruanes, Oscar M. Moreno-Arrones, David Saceda-Corralo, Ángela Hermosa-Gelbard, Ana Rita Rodrigues-Barata, Rubén Gil-Redondo, Emilio Garcia-Mouronte, Sergio Vano-Galvan
    TLDR Low-dose oral minoxidil improved hair growth in most pediatric patients with mild side effects.
    This study retrospectively reviewed the use of low-dose oral minoxidil (LDOM) in 45 pediatric patients (mean age 16 years) with androgenetic alopecia (87%) or telogen effluvium (13%) over a 2-year period. The treatment showed clinical improvement in hair density in 80% of patients, with hair loss stabilization in the remaining 20%. Adverse effects were mild and occurred in 25% of patients, with facial hypertrichosis being the most common. The study suggests that LDOM is a promising nonhormonal treatment option for pediatric hair disorders, though further research is needed to confirm its safety and efficacy.
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results

    Related Community Posts Join

    6 / 1000+ results

    Related Research

    9 / 9 results